2022 Oncology Conjugated Antibody Analysis Tool: Gain a Competitive Edge in Your ADC Drug Surveillance & Intelligence – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Conjugated Antibodies in Oncology: Analytical Tool” report has been added to from ResearchAndMarkets.com offer.

Conjugated Antibodies in Oncology: Analytical Tool is the essential handbook for any business developer, BI/CI operator, or clinical developer who needs to be on top of this hot and fast-paced field of oncology. This unique product is truly the only tool of its kind and is designed to give you a competitive edge in your ADC drug monitoring and intelligence, allowing you to fuel your decision-making and advance your own interests.

Your conjugated antibodies in oncology: analytical tool covers more than 187 companies and partners who are currently developing 516 ADC drugs, 390 of which are in active development in cancer on 153 different targets. All data and/or analysis in the analytics tool belongs to you and the data/graphs/tables can be easily exported to Excel/PDF and various graphical formats to be mixed with your own proprietary information.

For 20 years, we have been supporting better decision-making in the oncology drug development industry. Your Oncology Conjugated Antibodies: Analytical Tool is based on two decades of proven methodology and transforms your computer desktop into a high-capacity workbench in your chosen field.

Before even launching this tool, you have already eliminated the hundreds of hours of work required to discover, process and reconstruct the thousands of sources that our team of highly experienced and dedicated oncology content specialists has made for you.

Simply put, our mission is to fuel your oncology knowledge, making you the first to know about the very first technologies and startups, emerging clinical trial results, drug approvals and the ever-changing competitive landscape.

Let our expertise work for you

With a simple point-and-click interface, you can navigate the current development environment, explore specific areas such as ongoing combination trials, biomarker analysis, selected scientific abstracts, and more. and generate Drug Profiles, Drug Target Profiles and Company Profiles (including Business Development & Licensing Contacts). Any analysis you generate is packed with ready-to-present charts and tables for use in your reports and presentations.

Your key to accessing development at key global cancer meetings

Conjugated Antibodies in Oncology: Analytical Tool is continuously updated according to twelve of the world’s most influential oncology meetings (AACR, ASCO, ASGCT, ASH, CMIT, EHA, EORTC-NCI-AACR, ESMO, SITC and BIO (International, Europe If you’re unable to attend either conference in person, this analytics tool ensures you don’t miss the important take-home messages you need to know.

Run Combination Therapy Analysis Like No Other

Conjugated Antibodies in Oncology: Analytical Tool provides a comprehensive analysis of combination therapies, allowing you to analyze combination therapies from multiple angles; from a single drug to virtually any oncology drug sample of interest.

Unparalleled biomarker monitoring

We also provide exceptional clinical biomarker monitoring and analysis in oncology, highlighting clinical phenotyping and patient stratification in trials. This analysis is based on our monitoring of the presence and use of over 1,000 biomarkers in tens of thousands of cancer clinical trials.

Support and inspiration at your fingertips

You also have access to a great selection of hands-on training videos showing best practices for things like competitive pipeline analysis to plenty of real-life case examples from other users of our analytics tools.

A tool to grow and keep you informed

Unlike a static report that only represents a particular snapshot in time, all analytics tools come with one year of online access to bi-weekly content and feature updates, pipeline alerts, and online support, etc. You can choose to renew your access. to these updates and support on an annual basis or upgrade to our industry-leading full-service platform covering all oncology drug development, 1stOncology.

Conjugated Antibodies in Oncology: The analytical tool achieves this by continuously analyzing ADC development and reporting:

  • Offers and collaborations

  • New technologies/drugs (from patents, grants, abstracts (see conference coverage), etc.)

  • Funding/Grants/IPO

  • Filings and Approvals

  • Development and results of the latest clinical trials

  • Recently launched clinical trials

  • Conference Coverage of the top 12 global oncology meetings*

  • Quarterly and annual reports

This puts you in control of most, if not all, day-to-day developments in your field while benefiting from one of the most comprehensive competitive review and assessment tools available on the market today!

Identify, prioritize and direct the scientific assessment of opportunities and competition in oncology based on several factors such as:

  • Emerging technologies

  • Target novelty

  • Recent funding

  • Early and late stage pipeline

  • Development of companion biomarkers/diagnostics (presented below)

  • Seized offers and alliances

  • Conference monitoring of major global cancer meetings (featured below)

  • Combination therapy choices (shown below)

  • Result of clinical trials

  • Selection of indications and choice of extension

  • Drug repositioning opportunities

For more information about this report visit https://www.researchandmarkets.com/r/nwh3ns